Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2200 of 2873 entries
View as:

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase: N/A Priority: Normal
NCT ID: NCT04728230 Org: User:
Start: 01/05/21 End: 12/31/25 Due: 12/31/26

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

Phase: N/A Priority: Normal
NCT ID: NCT06651580 Org: User:
Start: 04/01/21 End: 02/02/27 Due: 02/02/28

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Phase: N/A Priority: Normal
NCT ID: NCT00883688 Org: User:
Start: 07/31/09 End: 04/30/15 Due: 04/30/16

Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes

Phase: N/A Priority: Normal
NCT ID: NCT04185337 Org: User:
Start: 01/26/21 End: 02/25/25 Due: 02/25/26

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Phase: N/A Priority: Normal
NCT ID: NCT06207812 Org: User:
Start: 01/19/24 End: 01/12/26 Due: 01/12/27

Xeloda (Capecitabine) and External Beam Radiation

Phase: N/A Priority: Normal
NCT ID: NCT00916578 Org: User:
Start: 06/05/09 End: 06/06/17 Due: 06/06/18

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06207305 Org: User:
Start: 01/30/24 End: 01/02/28 Due: 01/02/29

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02689440 Org: User:
Start: 02/19/16 End: 12/31/40 Due: 12/31/41

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase: N/A Priority: Normal
NCT ID: NCT04256941 Org: User:
Start: 05/31/19 End: 09/22/23 Due: 09/22/24

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05819892 Org: User:
Start: 07/17/23 End: 03/01/28 Due: 03/01/29

Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04874493 Org: User:
Start: 03/10/21 End: 02/02/27 Due: 02/02/28

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT02959463 Org: User:
Start: 05/01/17 End: 12/31/25 Due: 12/31/26

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01591356 Org: User:
Start: 07/01/15 End: 04/30/25 Due: 04/30/26

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00533585 Org: User:
Start: 05/31/06 End: 01/31/16 Due: 01/31/17

Patient Considerations of Social Media Account Management After Death

Phase: N/A Priority: Normal
NCT ID: NCT05035667 Org: User:
Start: 12/22/20 End: 12/31/26 Due: 12/31/27

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02626130 Org: User:
Start: 03/30/16 End: 06/20/22 Due: 06/20/23

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05766891 Org: User:
Start: 10/12/23 End: 12/31/28 Due: 12/31/29

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02257138 Org: User:
Start: 02/12/15 End: 03/19/21 Due: 03/19/22

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

Phase: N/A Priority: Normal
NCT ID: NCT05056857 Org: User:
Start: 10/01/21 End: 10/31/26 Due: 10/31/27

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01263782 Org: User:
Start: 05/17/11 End: 08/15/17 Due: 08/15/18

An Evidence Based Smoking Cessation Program for Persons Living With HIV/AIDS (Project Legacy)

Phase: N/A Priority: Normal
NCT ID: NCT02029612 Org: User:
Start: 04/30/14 End: - Due: -

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00893997 Org: User:
Start: 07/31/06 End: 03/31/09 Due: 03/31/10

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01162785 Org: User:
Start: 04/30/11 End: 11/30/16 Due: 11/30/17

Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal
NCT ID: NCT03207542 Org: User:
Start: 07/31/18 End: 07/31/21 Due: 07/31/22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Phase: N/A Priority: Normal
NCT ID: NCT01446133 Org: User:
Start: 12/12/11 End: 12/31/24 Due: 12/31/25